Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan for borderline pulmonary arterial hypertension in systemic sclerosis
2014-001882-28Phase 2Completed
- Sponsor
- Thoraxklinik am Universitätsklinikum Heidelberg
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) and systemic sclerosis (SSc) comparing Ambrisentan with Placebo (2 arms). Primary endpoint: Change in mean pulmonary arterial pressure. Started Aug 2014; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2014-001882-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001882-28.